keratoconjunctivitis sicca

(redirected from Restasis)

keratoconjunctivitis

 [ker″ah-to-kon-junk″tĭ-vi´tis]
inflammation of the cornea and conjunctiva.
epidemic keratoconjunctivitis a highly infectious form, commonly with regional lymph node involvement, occurring in epidemics; an adenovirus has been repeatedly isolated from affected patients.
phlyctenular keratoconjunctivitis a form marked by formation of a phlyctenule (small lesion) at the corneal limbus.
keratoconjunctivitis sic´ca a condition marked by hyperemia of the conjunctiva, thickening and drying of the corneal epithelium, and itching and burning of the eye. Called also dry eye.

ker·a·to·con·junc·ti·vi·tis sic·ca

keratoconjunctivitis associated with decreased tears.
See also: Sjögren syndrome.

keratoconjunctivitis sicca

dryness of the cornea caused by a deficiency of tear secretion in which the corneal surface appears dull and rough and the eye feels gritty and irritated. The condition may be associated with erythema multiforme, Sjögren's syndrome, trachoma, and vitamin A deficiency. Methylcellulose artificial tears may give some relief, as can insertion of plugs into the punctae and use of cyclosporine drops.
Dryness of eyes, often due to decreased tear secretion, which occurs in Sjögren syndrome, autoimmune disorders—systemic lupus, rheumatoid arthritis, scleroderma, sarcoidosis—amyloidosis, hypothyroidism, vitamin A deficiency, and in periorbital lymphoproliferative disorders

ker·a·to·con·junc·ti·vi·tis sic·ca

(ker'ă-tō-kŏn-jŭngk'ti-vī'tis sik'ă)
A chronic mucopurulent conjunctivitis, sometimes leading to corneal ulceration and scarring, due to deficit of the aqueous component of tears.
Synonym(s): dry eye syndrome.

keratoconjunctivitis sicca

Dry eye. A state of inadequate wetting and lubrication of the cornea as a result of defective tear production. This results from damage to the tear glands by the same AUTOIMMUNE DISEASE process that causes RHEUMATOID ARTHRITIS, SJOGREN'S SYNDROME, systemic lupus erythematosus and other related conditions. Dry eye is common in all these disorders. There is constant discomfort, foreign-body sensation and sometimes pain and the condition may progress to infection and ulceration of the cornea. Treatment is by the regular use of artificial tears.

ker·a·to·con·junc·ti·vi·tis sic·ca

(ker'ă-tō-kŏn-jŭngk'ti-vī'tis sik'ă)
A chronic mucopurulent conjunctivitis, sometimes leading to corneal ulceration and scarring.
Synonym(s): dry eye syndrome.

keratoconjunctivitis sicca (ker´ə-tōkənjungk´tivī´tis sik´ə),

keratoconjunctivitis

inflammation of the cornea and conjunctiva.

chronic immune-mediated keratoconjunctivitis syndrome
see chronic superficial keratitis.
infectious keratoconjunctivitis
see also infectious bovine kerato conjunctivitis. Caused by Moraxella bovis, Histoplasma capsulatum, Chlamydiae, Mycoplasma spp.
proliferative keratoconjunctivitis
see nodular fasciitis.
keratoconjunctivitis sicca
a condition marked by hyperemia of the conjunctiva, thickening and drying of the corneal epithelium, secondary to quantitative and qualitative deficiencies in the tear film. Deep keratitis and corneal ulceration may occur. Often a tenacious, stringy mucoid discharge accumulates in the conjunctival sac. Called also dry eye.
References in periodicals archive ?
RESTASIS did not increase tear production in patients using anti-inflammatory eye drops or tear duct plugs.
Doctor: I'm writing you a prescription for Restasis.
Prescription options may include Lacrisert, a small, clear insert that dissolves throughout the day to stabilize the eye's tear film, and Restasis (cyclosporine A) eye drops, which increase tear production.
In addition, the new anti-allergy and dry eye medicines that have become available in the last two to three years (for example, endura, restasis, and xibrom), are included in the publication.
Food and Drug Administration-approved prescription treatment for dry eyes, Restasis (cyclosporine ophthalmic emulsion 0.
closed higher Tuesday, cheered by Wall Street after the company received Food and Drug Administration approval for Restasis, which increases production of tears in patients with chronic dry-eye disease.
Food and Drug Administration (FDA) has received Akorn's Abbreviated New Drug Application (ANDA) containing a "Paragraph IV" patent certification seeking approval to market a generic version of Allergan's Restasis (cyclosporine ophthalmic emulsion) 0.
Presently, Allergan has four programs for alternatives to its dry-eye medication, Restasis, which is at risk of generic competition.
Should over-the-counter remedies prove ineffective, consult with your physician about a prescription drug called Restasis that works to increase the eye's tear production.
Richards Teams Up with Allergan, the Makers of RESTASIS (cyclosporine ophthalmic emulsion) 0.
An anti-inflammatory eye drop called Restasis is FDA-approved for the condition.
The current US market for DES is dominated by Restasis, in addition to as-needed relief with artificial tears.